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Ranitidine and cimetidine differ in their in vitro and in vivo effects on human
colonic cancer growth
JA Lawson, WJ Adams and DL Morris
UNSW Department of Surgery, The St. George Hospital, Kogarah Sydney, N.S.W. 2217 Australia.
Summary Histamine has recently been shown to be a growth factor for some gastric and colorectal cancer
cells. Previous studies have shown that cimetidine blocks in vitro and in vivo histamine-stimulated growth and
cAMP release from the human colonic cancer cell line, C170. In this study, ranitidine, another H2 receptor
antagonist, did not affect either basal or histamine-stimulated in vitro proliferation of C170, and failed to
prevent cAMP release in vitro. Ranitidine did not inhibit in vivo growth of C170 at a dose of 1, 10, 25, 50 or
100 mg kg-', in contrast to 50 mg kg -day-' cimetidine, which produced 39.3% inhibition of tumour volume
(P<0.01) after 23 days' treatment. Ranitidine did not inhibit in vivo histamine-stimulated growth ofC170 cells.
LIM2412, another colonic cancer cell line, was significantly stimulated by both cimetidine and ranitidine in
vivo. Ranitidine had no effect on in vitro cell proliferation.
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We recently reported that histamine is a growth factor for
some colorectal cancer cell lines (Adams et al., 1994a). The
histamine receptor antagonist, cimetidine, has been found to
significantly slow the growth of experimentally induced
gastrointestinal cancers (Adams et al., 1993, 1994; Watson
et al., 1993) and improve survival in patients with
gastrointestinal malignancies (Tonnesen et al., 1988; Adams
and Morris, 1994; Matsumotos, 1995). Whether this is due to
the inhibitory effect of cimetidine on suppressor T-
lymphocyte activity (Osband et al., 1981), its stimulation of
natural killer (NK) cell activity (Hellstrand and Hermodsson,
1986; Allen et al., 1987; Kikuchi et al., 1985), its stimulation
of interleukin 2 production in helper T cells (Gifford and
Tilberg, 1987) or its blocking of the direct mitogenic effect of
histamine on colon cancer (Adams et al., 1994), is unknown.
Ranitidine is a more potent and clinically well-tolerated
histamine H2 receptor antagonist than cimetidine. There has
been some conflict in the literature as to whether ranitidine
and cimetidine have similar effects on the immune system
(Nielson et al., 1989a, b; Halm et al., 1995).
The effects of ranitidine on cancer growth are not well
investigated. The aim of this paper was to examine the effect
of ranitidine on the growth of colon cancer, and its effect on
the histamine-sensitive human colorectal cancer cell lines,
C170 and LIM2412.
Method
Cell lines
C170 cells are an adherent cell line (Durrant et al., 1986),
which were derived from a patient with a Dukes' C colonic
adenocarcinoma (CRC Laboratories, Nottingham, UK).
LIM2412 cells are a suspension cell line with some adherent
cells present (Whitehead et al., 1992). This cell line was
derived from a patient diagnosed with a poorly differentiated
colonic adenocarcinoma (Ludwig Institute, Melbourne,
Australia). Both these cell lines were grown in RPMI-1640
with 10% fetal calf serum (FCS) under 5% carbon dioxide
and refed twice weekly.
In vitro cell proliferation assay
Cells were resuspended in serum containing RPMI-1640 at a
concentration of 1 x 104 cells 0.2 ml-1 and incubated
overnight in a 96-well microtitre plate. The supernatant was
then removed and replaced with 0.6 imol of thymidine
(Sigma, St Louis, MO, USA) in serum-free media. After 24 h
the supernatant was removed and replaced with histamine
(Sigma) and/or ranitidine hydrochloride (Glaxo, Greenford,
UK) in serum-free media with untreated controls. Ranitidine
was added in replicates of at least three, over a concentration
range of 1 x 10-9 M to 1 X 10-6 M. Histamine was added to
the cells with/without ranitidine at a concentration range of
1 x 10-9 M to 1 x 10-7 M as 1 x 10-8 M most frequently
achieved maximal stimulation (Adams et al., 1994). Each
experiment was repeated three times. As a direct measure of
DNA replication (Kusyk et al., 1986), 0.1 pCi of methyl-['H]-
thymidine (DuPont, NEN, Boston, MA, USA) was added to
the wells and incubated for a further 8, 24 and 48 h. The cells
were then harvested using a cell harvester (PHD cell
harvester, Cambridge Technology, USA) and counted using
a beta-counter (Minaxi Tri-carb 4000 series, United
Technologies Packard, USA).
Statistical analysis
Results were calculated as a mean percentage of the control
(s.e.). Any statistical differences were calculated using a one-
way analysis of variance (ANOVA). A P-value of less than
0.05 was considered significant.
Quantification of intracellular cyclic adenosine monophosphate
(cAMP)
Intracellular cAMP was measured using a monoclonal
antibody-based kit (Amersham, UK). C170 cells were
harvested and resuspended in serum-free RPMI-1640 with
0.5 mM isobutyl methylxanthine (IBMX, Sigma) at 1.25 x 105
cells 0.25 ml-', and incubated in polypropylene tubes at 37°C
for 10 min. Histamine aliquots of 0.125 ml were added at a
concentration range of 1 x 10-' to 1 x 10-3 M, with or
without the addition of ranitidine at 1 x 10-4 M. Forskolin,
a direct stimulator of adenylate cyclase (Seamon and Daly,
1981), was added in triplicate at a final concentration of
1 x 10-6 M. Following the addition of histamine, the cells
were incubated for 10 min at 37°C (Shanin et al., 1985), then
centrifuged for 3 min at 2000 r.p.m. The supernatant was
removed and the cells fixed in 0.5 ml of 0.001 M hydrochloric
acid-ethanol chilled at 4°C, to allow for cAMP extraction.
After thorough mixing, the tubes were further centrifuged for
15 min at 15 000 r.p.m. Supernanant (0.4 ml) was removed
and placed into fresh tubes and the contents dried using a
Speed Vac Concentrator (model SVC1O0H, Savant Instru-
ments, NY, USA) at 60°C for 60 min. These were then
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reconstitued in 2 ml of buffer provided in the kit and cAMP
measured.
Results were expressed as fmol of cAMP 1 x 10- cells.
Each drug concentration was measured in triplicate and the
results expressed as a mean (s.e.).
Nude mouse model
All animal procedures were carried out under the approval of
the University of New South Wales, Australia, Animal Care
and Ethics Committee.
Effect ofranitidine on in vivo basal C170 or LIM2412 tumour
growth
C170 or LIM2412 cells were injected subcutaneously into 6-
9 week male nu/nu mice (Ansto, Lucas Heights, Australia) at
a concentration of 1 x 106 cells 0.1 ml-' RPMI-1640 with
10% FCS. Each treatment group had ten animals per group
unless otherwise stated, based on our previous studies, which
showed 50 mg kg-' day-' cimetidine to inhibit C170 tumour
growth by 44% of the control (Adams et al., 1994).
Animals with C170 tumours received 0, 0.1, 0.2,
0.4 mg ml-' ranitidine hydrochloride in the drinking water,
in two separate experiments, which produced an approximate
daily intake of 25, 50 or 100 mg kg-' day-' of ranitidine
hydrochloride, commencing immediately following tumour
injection. Animals inoculated with LIM2412 cells were
randomised to receive ranitidine 10, 25 and 50 mg kg-'
given in the drinking water. These calculations are based
on the observations in our laboratory that the mice drink an
average of 5 (s.e. 0.6) ml day-' (Adams et al., 1994). The
water bottles containing ranitidine hydrochloride were
replaced every 2 days.
Tumour areas were measured twice weekly using vernier
callipers. Tumour volumes were calculated using the formula
0.5 length x (width)2 (Euhus et al., 1986). The mice were
sacrificed after a maximum of 28 days after inoculation.
Effect of concurrent histamine and ranitidine administration on
C170
C170 cells were injected subcutaneously, as above. The
animals were than randomly allocated to receive either
control (phosphate-buffered saline; PBS) or histamine
(1 x 10- M mmin- ) via a 14 day subcutaneous Alzet mini-
osmotic pump (Alza Corporation, Palo Alto, CA, USA).
Both the control and histamine-treated group received
0.4 mg ml-' (approximately 100 mg kg-' day-') of raniti-
dine hydrochloride in the drinking water. Treatment
continued for 22 days after injection. Mini-osmotic pumps
were replaced after 14 days.
Effect of histamine, cimetidine and ranitidine on in vivo
LIM2412 growth
LIM2412 cells were injected as above. The control group
received water ad libitum. Ranitidine and cimetidine was
administered via the drinking water at a dose of 50 and
100 mg kg-' day-' respectively. Histamine was administered
via a mini-osmotic pump at a dose of 1.2 x 10-v M day-' on
the opposite flank to the tumour site. Treatment continued
for 25 days after tumour inoculation.
Direct comparison of ranitidine and cimetidine administration
on C170
C170 xenografts were established as above and animals
randomised to cimetidine 50 mg kg-' day-', ranitidine 1 or
10 mg kg-' day-' in the drinking water, or untreated
control.
Statistical analysis
A one-way analysis of variance (ANOVA) was used to
measure the significant differences as a result of the different
treatment regimens in all experiments. Only animals with
actively growing tumours were used as part of the statistical
analysis.
Results
In vitro: C170
Ranitidine had no effect on basal growth in five experiments
in which histamine produced a stimulation in cell prolifera-
tion, of which three were significant (P<0.05) to a maximum
of 142.8% of control at 1 X 10-8 M histamine (Table I).
Ranitidine, at a concentration of 1 x 10-8 to 1 x 10-6 M,
failed to inhibit the histamine-stimulated cell proliferation.
Histamine did not stimulate cell proliferation in assays
shorter than 48 h (data not shown).
LIM2412
Neither histamine nor ranitidine affected basal growth of
LIM2412 cells. Because of our inability to show a significant
in vitro stimulation with histamine we were unable to study
the effect of ranitidine on histamine-stimulated in vitro
growth (data not shown).
Quantification of intracellular cAMP, C170
The addition of histamine alone to C170 cells significantly
stimulated cAMP production in a dose-dependent manner.
This effect was antagonised by cimetidine (Figure 1). In
contrast, ranitidine did not inhibit histamine-stimulated
cAMP release.
Table I Effect of ranitidine and histamine on in vitro cell proliferation of C170 cells after 48 h with a tritiated thymidine label
Ranitidine Histamine 1 2 3 4 5
0 - 100.0 (2.3) 100.0 (4.4) 100.0 (3.8) 100.0 (12.9) 100.0 (4.2)
lX 10-8 M - _ _ 119.1 (8.4)* - -
1 X 10 7 M - - 98.1 (8.3) 121.1 (4.0)* - -
1 X 1e M - 106.5 (4.2) - - 114.0 (13.4) 106.2 (6.5)
1 X 10 9 M 95.6 (7.2) 125.3 (11.0)* - 114.3 (13.4) 115.1 (7.7)
1 X 10 8 M 142.8 (21.0)* 132.5 (7.5)* 117.3 (4.3)* 126.2 (14.6) 119.9 (7.7)
- 1 X 10 7 M 141.8 (23.0)* 106.1 (9.6) - 126.9 (14.6) 112.1 (12.4)
xlo 8 M
I xlo 8 M - - 114.2 (6.2)* - -
X 107 M lX 10-8 M _ 128.4 (8.5)* 124.4 (9.1) - -
1 X 10. M 1 X 10 8 M 121.8 (10.0) - - 116.1 (16.1) 121.6 (8.2)
Results are expressed as a mean per cent (s.e.m.) ofthe control ofeach experiment (n=5). Results offive separate experiments are presented.
*P < 0.05 vs control using a one-way ANOVA.Ranitidine and colon cancer
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Effect of ranitidine and cimetidine on basal C170 growth in
vivo
The administration of oral ranitidine to mice bearing C170
tumours had no effect at 1 or 10 mg kg-' day-' (Figure 2).
Higher doses ofranitidine (25, 50 or 100 mg kg-' day-') also
had no effect on tumour growth (data not shown). This is in
contrast to tumours in animals receiving cimetidine at a dose
of 50 mg kg-' day-', which were inhibited maximally to
48.4% of the control after 18 days' treatment (P=0.019)
(Figure 2).
Effect ofhistamine, cimetidine and ranitidine on in vivo
LIM2412 growth
The administration of 50 mg kg-' day-' ranitidine to mice
bearing LIM2412 tumours produced significant stimulation in
tumour growth of 90.6% (P<0.01) (Figure 3) and 98.4%
(P<0.01) (Figure 4) of the untreated control in two separate
experiments. Ranitidine (25 mg kg-') produced some stimu-
lation but was not significant (P= 0.12) whereas 10 mg kg-'
ranitidine had no effect (P=0.77) (Figure 3).
Cimetidine, at a dose of 100 mg kg-' day-' produced a
significant stimulation of 94.9% (P=0.014) (Figure 4) to
LIM2412, whereas histamine produced a trend to stimulation
of 70.8% (P=0.063).
*
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Figure 1 The differential effects of cimetidine and ranitidine on
histamine-stimulated cAMP release of C170 cells. Results are
expressed as the mean cAMP produced in fmol cAMP per 10000
cells in replicate. Statistical differences were assessed using a one-
way ANOVA. *P<0.01 vs control; **P<0.05 vs control. 0,
control; A, 1 x 10-4M cimetidine; * 1 x 10-4M ranitidine.
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Effect ofconcurrent histamine and ranitidine administration on
in vivo C170 growth
Histamine pumped subcutaneously achieved a 30.4%
stimulation in terminal tumour volume, as compared with
the control, which, in this experiment, did not achieve
statistical significance (P=0.30). Ranitidine alone stimulated
tumour growth by 26.2% of the control (P=0.40), but
again was not significantly significant. The addition of
100 mg kg-' day-' ranitidine concurrently to animals
bearing histamine pumps did not prevent this trend (27.0%
of the control) (histamine vs ranitidine/histamine; P<0.8;
data not shown).
Discussion
Ranitidine had no effect on either basal or histamine-
stimulated growth of C170 either in vitro or in vivo and
had no effect on histamine-stimulated cAMP production.
This is in marked contrast to the effects of cimetidine,
another H2 receptor antagonist, which we have found in this
series of experiments and previously to inhibit histamine-
stimulated C170 growth in vitro and in vivo, as well as being
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Figure 2 Direct comparison of oral cimetidine (50mgkg-'
day-) and ranitidine (1 and 10mgkg-1 day-) on the in vivo
growth ofC170 after 23 days treatment. Results were expressed as
the mean (s.e.) viable tumour volume (mm3) on various days after
tumour inoculation. A one-way analysis of variance was used to
determine any statistical differences between treatment groups.
*P<0.01 vs control, **P<0.05 vs control. 0, control (n=9); 0,
ranitidine (1 mgkg-' day-) (n=9); V, ranitidine (10mgkg-'
day-) (n=9); *, cimetidine (50mgkg-' day-) (n=9).
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Figure 3 Effect of oral ranitidine (10, 25 and 50mgkg' day')
on the in vivo growth of LIM2412 after 27 days. Results were
expressed as the mean (s.e.) viable tumour volume (mm3) on the
various days after tumour injection. A one-way ANOVA was
used to determine any statistical differences between treatment
groups, after days 23 and 27 of ranitidine treatment. Ranitidine
treatment at 50mgkg-1 day-' significantly inhibited LIM2412
tumour volumes (*P<0.01). There was no significant difference in
the resulting tumour volumes with 25mgkg'- day-' ranitidine vs
control (P=0.12) or 10mgkg-1 day-' ranitidine vs control
(P=0.12) or 10mgkg-' day-' ranitidine vs control (P=0.77).
0, Control (n= 13); 0, ranitidine (50mgkg-1 dayl) (n= 12);
V, ranitidine (25mgkg-1 day-) (n=15); *, ranitidine
(10mgkg-' day-') (n = 16).
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Figure 4 Effect of histamine (1.2 x 10-7M day- ), ranitidine
(50mgkg- day-1) and cimetidine (I00mgkg-l day-1) on the in
vivo growth of LIM2412. Histamine was administered via a 14
day subcutaneous mini-osmotic pump that was replaced after 14
days (Alza Corporation, Palo Alto, CA, USA). Results were
expressed as the mean (s.e.) tumour volumes on various days after
tumour inoculation. A one-way ANOVA was used to determine
any differences between treatment groups after 23 days'
treatment. Histamine and cimetidine significantly stimulated
tumour growth (*P<0.05). Ranitidine significantly stimulated
tumour growth (**P<0.01). 0, Control (n=18); b, histamine
(1.2 x 10-7M day-') (n= 10); 0, cimetidine (I00mgkg' day-)
(n = 11); A, ranitidine (50mgkg-1 day-') (n = 13).
able to inhibit histamine-stimulated cAMP production by
C170 cells (Adams et al., 1994a).
These results are surprising because ranitidine is a 4-9
times more potent antagonist at the H2 receptor than
cimetidine on the parietal cell (Woodings et al., 1983). This
suggests a mechanism of action for cimetidine on cancer cells
that is independent of classical H2 receptor antagonism.
Although both cimetidine and ranitidine are both H2 receptor
antagonists, they are quite different structurally and possess
different binding affinities at other sites (Lin, 1991). It would
seem likely that colon cancer cells carry histamine receptors
different in structure to parietal type 2 receptors and these
may lend themselves to the development of specific receptor
antagonists.
Our cAMP studies certainly indicate that there is a
receptor-mediated effect of histamine in colon cancer cells
and the finding that cimetidine but not ranitidine affects
histamine-stimulated cAMP release, in vitro and in vivo
growth is strong evidence that this receptor system-
responsible for the histamine-stimulated growth and is other
than a typical H2 receptor. Whether the functional histamine
receptor of gastric cancer (Watson et al., 1993) and
melanoma (Whitehead et al., 1988) are identical to C170 is
unknown.
Previously, LIM2412 was demonstrated to be stimulated
by histamine in vitro and inhibited by cimetidine in vivo
(Adams et al., 1994a). In the current experiments, histamine
pumped into the opposite side of the tumour site produced a
significant stimulation of tumour growth by 71.9% of the
control. Ranitidine produced a significant in vivo stimulation
in both experiments that appeared to be dose dependent
(Figures 3 and 4). We did not see evidence of in vitro
stimulation (data not shown). The mechanism for this
stimulation is uncertain and may not be H2 receptor
mediated. In the current studies, cimetidine did not inhibit
in vivo growth of LIM2412 but produced a significant
stimulation. The reason for the variations in response of
LIM2412 is not currently understood. This significant
stimulation seen with ranitidine and cimetidine are clearly
of concern and could be explained by agonist activity.
Tutton and Barkla (1983) previously examined the effects
of the H2 receptor antagonists cimetidine, metiamide and
ranitidine on the growth of colonic tumours using two
models - a carcinogen-induced rat model and fresh ex vivo
tumours in thymectomised mice. In contrast to our results,
there was significant inhibition in tumour growth by ranitidine
given twice daily by intraperitoneal injection at a dose of
5 mg kg-' day-' whereas cimetidine had no effect. There are
many differences in these experiments compared with the
present series. We used oral rather than parenteral adminis-
tration of drugs, and the doses of cimetidine we used were
considerably higher than those used by Tutton and Barkla
(1983). Also our drug treatment commenced immediately after
tumour inoculation, whereas Tutton and Barkla (1983)
commenced treatment on day 24 after inoculation. Our
studies with ranitidine used a greater dose range.
In addition to cell membrane receptors, intracellular
histamine receptors have also been found to have important
growth-controlling activity. Brandes and La Bella (1993)
demonstrated binding by cimetidine and ranitidine to this
intracellular histamine receptor to be both weak and equal
(5 x 10-3 M) so this site is unlikely to account for the
difference we have seen between cimetidine and ranitidine.
Halm et al. (1995) demonstrated that cimetidine, but not
ranitidine or famotidine, has an immunomodulating effect on
peripheral blood mononuclear cells in gastric cancer patients.
Again, this suggests that ranitidine and cimetidine have
differing actions on non-parietal H2 receptors.
The survival advantage found in patients receiving
cimetidine in gastric cancer (Tonneson et al., 1988) and
trends to survival advantage from colorectal cancer, in three
trials ofdifferent designs (Adams and Morris, 1994; Svendsen
et al., 1995; Matsumoto 1995) suggest a role for this drug as
a non-toxic inhibitor of tumour growth. Our data, however,
suggest that very different results may be achieved by some
histamine antagonists in some circumstances. The possibly
novel nature (non-classical H2) of the growth-regulating
histamine receptor seen in at least some human colorectal
cancers may allow development of more specific and
hopefully even more active antagonists.
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